

5 June 2026

REF: 26867

8th Floor
10 South Colonnade
Canary Wharf
London
E14 4PU

Tel: 020 3928 2000
Email: nhsr.appeals@nhs.net

**APPEAL AGAINST NHS GREATER MANCHESTER
ICB DECISION TO REFUSE AN APPLICATION BY
KIAG MEDICAL LTD FOR INCLUSION IN THE
PHARMACEUTICAL LIST AT OFFICE 2-3, 2ND
FLOOR, 761 WILMSLOW ROAD, MANCHESTER,
M20 6RN UNDER REGULATION 25**

1 Outcome

- 1.1 The Pharmacy Appeals Committee (“Committee”), appointed by NHS Resolution, quashes the decision of the Commissioner and redetermines the application.
- 1.2 The Committee determined that the application should be granted.

A copy of this decision is being sent to:

Rushport Advisory LLP on behalf of Kiag Medical Ltd
PCSE on behalf of Greater Manchester ICB

REF: 26867

8th Floor
10 South Colonnade
Canary Wharf
London
E14 4PU

Tel: 020 3928 2000
Email: nhsr.appeals@nhs.net

**APPEAL AGAINST NHS GREATER MANCHESTER
ICB DECISION TO REFUSE AN APPLICATION BY
KIAG MEDICAL LTD FOR INCLUSION IN THE
PHARMACEUTICAL LIST AT OFFICE 2-3, 2ND
FLOOR, 761 WILMSLOW ROAD, MANCHESTER,
M20 6RN UNDER REGULATION 25**

1 The Application

By application dated 22 June 2025, Kiag Medical Ltd (“the Applicant”) applied to Greater Manchester ICB (“the Commissioner”) for inclusion in the pharmaceutical list at Office 2-3, 2nd Floor, 761 Wilmslow Road, Manchester, M20 6RN under Regulation 25. In support of the application it was stated:

- 1.1 In response to “If you are undertaking to provide appliances, specify the appliances that you undertake to provide (or write ‘none’ if it is intended that the pharmacy will not provide appliances)” the Applicant stated:

1.1.1 “N/A”

- 1.2 In response to why the application should not be refused pursuant to Regulation 31 the Applicant stated:

1.2.1 “While Regulation 31 allows an application to be refused where adequate local pharmaceutical services are already provided, such a decision must take into account the evolution of pharmacy services as part of integrated primary care, especially in light of nationally commissioned services like Pharmacy First and the New Medicine Service (NMS). These services, delivered through community pharmacy, are integral to reducing GP workload, improving clinical outcomes, and broadening patient access all key NHS objectives. My application directly supports these aims.

1.2.2 Pharmacy First: A Clinically Led Initiative to Reduce GP Demand

1.2.2.1 The Pharmacy First service, commissioned nationally from January 2024, enables pharmacists to treat seven common conditions without patients needing to see a GP. This includes:

Acute otitis media (although we will not be doing this as this requires a face to face appointment and will not be advertising this to patients

Impetigo

Infected insect bites

Shingles

Sinusitis

Sore throat

Uncomplicated urinary tract infections in women

1.2.2.2 By offering Pharmacy First through this application, I will:

1.2.2.3 Provide accessible, same-day treatment to patients, reducing NHS pressures Deliver clinically safe and regulated care in line with NHS England guidance

1.2.2.4 These services are not purely local in nature; their impact is national, and they must be supported by a network of capable providers, including digital and remote-capable pharmacies. Refusing this application would risk underutilising this strategic service expansion.

1.2.3 New Medicine Service (NMS): Supporting Adherence & GP Prescribing Outcomes

1.2.3.1 The New Medicine Service, another nationally commissioned and evidence backed initiative, helps patients recently prescribed certain long-term medications to understand and adhere to treatment. It is especially important for:

Hypertension

Asthma and COPD

Diabetes

Anticoagulation

Mental health medicines

1.2.3.2 Delivering NMS through my pharmacy would:

1.2.3.3 Improve medication adherence, reducing avoidable hospital admissions. Free up GP time by offering post-prescription support and follow-up outside of general practice

1.2.3.4 Support clinical outcomes, especially for patients managing new long-term conditions

1.2.3.5 By managing these interventions efficiently and at scale, my service complements primary care and upholds the NHS Long Term Plan's ambition to extend the role of community pharmacy in personalised care.

1.2.4 Nationally Strategic Services Are Not Limited by Local Proximity

1.2.4.1 While other pharmacies may be present locally, not all are equipped, commissioned, or structured to deliver full-service digital access, national reach, or scalable capacity to handle Pharmacy First consultation and NMS delivery

1.2.4.2 Coordination of care for vulnerable or underserved groups who struggle to access in-person services.

1.2.4.3 The NHS' strategic intent is clear: pharmacy is no longer just a dispensing hub. It is a clinical partner in population health management. That requires enabling new providers especially those capable of high-quality, patient centred digital service rather than limiting access based solely on physical location.

1.2.5 Supporting Primary Care Networks and Integrated Care Systems

1.2.5.1 Pharmacy-based services like NMS and Pharmacy First contribute to broader goals within Primary Care Networks (PCNs) and Integrated Care Systems (ICSs) by:

1.2.5.2 Offering clinical triage, first contact care, and medicines optimisation

1.2.5.3 Enhancing same-day access capacity

1.2.5.4 Reducing reliance on A&E and urgent care

1.2.5.5 My application is consistent with the aim of redistributing clinical workload across the NHS and delivering care closer to the patient physically or digitally.

1.2.6 Conclusion:

1.2.7 In light of nationally commissioned services like Pharmacy First and the New Medicine Service, my application should not be refused under Regulation 31. These services are not merely supplementary, but core elements of the NHS primary care strategy. By enabling my pharmacy to provide these services, the NHS would be supporting its own goals of reducing pressure on GPs, improving patient access to care, and making best use of pharmacists' clinical skills."

1.3 In response to why the application should not be refused pursuant to Regulation 25(2)(a) the Applicant stated:

1.3.1 "N/A"

Pharmacy procedures

1.4 "Please explain how the pharmacy procedures used within the premises will secure:

(a) the uninterrupted provision of essential services during the opening hours of the premises, to persons anywhere in England who request those services, and

(b) the safe and effective provision of essential services without face to face contact between any person receiving the services, whether on their own or someone else's behalf, and the applicant or the applicant's staff.

- 1.5 Please describe the procedure that will be followed where a patient attends the premises and asks for one or more of the essential services.
- 1.6 You must ensure that you provide sufficient information within this application form to satisfy NHS England or the relevant delegated integrated care board on the above points. You are not required to submit your standard operating procedures for the premises but if you do they will be circulated to interested parties unless NHS England or the relevant delegated integrated care board is satisfied that the full disclosure principle does not apply.
- 1.7 “Our pharmacy has developed a set of comprehensive, fully compliant Standard Operating Procedures (SOPs) and infrastructure to ensure the uninterrupted provision of all essential services throughout our contractual opening hours, to any patient located anywhere in England. This is central to our operation as a Distance Selling Pharmacy and is achieved through the following measures:
- 1.8 Staffing and Operational Continuity
 - 1.8.1 The pharmacy is staffed by a Responsible Pharmacist and a trained support team during all opening hours. Staff rotas and a locum cover system are in place to ensure no gaps in service provision due to absence or unforeseen circumstances. SOPs include provisions for handover procedures, duty accountability, and out-of-hours support where necessary.
- 1.9 Electronic Prescription Service (EPS) Integration
 - 1.9.1 We are fully integrated with the NHS EPS, enabling real-time receipt, processing, and dispensing of prescriptions from any GP surgery in England. This ensures no geographic limitations on access to our services.
- 1.10 Multi-Channel Patient Access
 - 1.10.1 Patients can request and access services via a variety of non-face-to-face channels, including secure web portal, telephone, email, and support through NHS app. Our team is trained to support a diverse patient base, including those with accessibility needs, with translation, large print, and alternative contact methods available.
- 1.11 National Delivery Service

- 1.11.1 We work with reliable national courier partners offering next-day tracked delivery and urgent same-day services where clinically appropriate. Our dispatch procedures ensure secure, temperature-controlled packaging where needed, with full traceability and proof of delivery.
- 1.12 Business Continuity and Risk Management
 - 1.12.1 We maintain a comprehensive business continuity plan, including backup power, off-site access to key systems, and secondary suppliers for critical stock. Routine risk assessments and contingency drills ensure the team is prepared to maintain uninterrupted service delivery in all scenarios.
- 1.13 Clinical Governance and Quality Monitoring
 - 1.13.1 Ongoing audit, service monitoring, and patient feedback mechanisms ensure that services are delivered to high standards consistently across England.
- 1.14 Website
 - 1.14.1 We will have a website accessible
 - 1.14.2 Through this infrastructure, we guarantee uninterrupted provision of all essential services (e.g., dispensing, repeat dispensing, signposting, public health advice, disposal of unwanted medicines, etc.) to any person in England during our operational hours.
- 1.15 (b) the safe and effective provision of essential services without face to face contact between any person receiving the services, whether on their own or someone else's behalf, and the applicant or the applicant's staff.
 - 1.15.1 Our pharmacy operates under a fully remote service model, designed from the outset to deliver safe and effective essential services without any face-to-face interaction, in line with the specific requirements of a Distance Selling Pharmacy.
- 1.16 Remote Clinical Processes and Communication
 - 1.16.1 All clinical assessments, prescription interventions, and advice are conducted remotely using secure telephone, video call, or digital messaging platforms. The pharmacy has SOPs to guide remote consultation protocols, ensuring clinical appropriateness, patient understanding, and informed consent without face-to-face contact.
- 1.17 Electronic Prescription Handling and Dispensing
 - 1.17.1 Prescriptions are received via EPS, processed by the pharmacist, and dispensed according to standard procedures with full audit trail and clinical checks.
 - 1.17.2 Where prescription queries arise, these are resolved via telephone or digital communication with the prescriber or patient.

1.18 Remote Access to Essential Services

1.18.1 Essential services such as the New Medicine Service (NMS) and Pharmacy First (where eligible) are delivered via structured remote consultation templates and pharmacist follow-up calls. Public health advice and signposting are provided via leaflets included with medication, website resources, and telephone consultations.

1.19 Patient Information and Counselling Materials

1.19.1 All dispensed medicines are accompanied by clear, written patient information, and additional leaflets are included where relevant (e.g., on lifestyle, safety, or managing conditions).

1.19.2 Patients are invited to contact the pharmacist via dedicated phone lines for any questions, with calls recorded for safety and training purposes.

1.20 No Physical Patient Access to Premises

1.20.1 Our premises are not accessible to the public, ensuring that no face-to-face interaction occurs with patients or their representatives. All interactions are conducted remotely, in accordance with the NHS DSP requirements and our Information Governance policies.

1.21 Safeguarding and Escalation Procedures

1.21.1 Procedures are in place for the remote identification of safeguarding concerns, including protocols for escalation to local services or prescribers when needed.

1.22 All our procedures are specifically designed to meet the regulatory requirements of a Distance Selling Pharmacy, enabling the uninterrupted, safe, and effective provision of essential services to anyone in England entirely without face-to-face contact, while maintaining the same high standards of clinical care, patient safety, and regulatory compliance as a traditional pharmacy setting.

1.23 As a Distance Selling Pharmacy, we are fully compliant with the requirements set out in The NHS (Pharmaceutical Services) Regulations 2013, which clearly state that no part of the essential services may be provided face-to-face at the pharmacy premises.

1.24 Our premises are not open to the public, and procedures are in place to ensure that patients or their representatives do not attend or access the pharmacy for any purpose, including requesting or collecting services or medications. This is because our premises is on the second floor of a commercial building which can not be accessed except with key code access to building.

1.25 If a member of the public attends the premises in person and requests one or more essential services, the following procedure will be followed:

1.26 Procedure for Unscheduled Patient Attendance at the Premises:

1.27 Informing the Patient Politely

- 1.27.1 A designated staff member will inform the patient, in a professional and respectful manner, that this pharmacy does not provide services in person and that the premises are not open to the public under NHS distance selling regulations.

1.28 Explanation of Service Model

- 1.28.1 The patient will be given a brief explanation that all essential services (e.g. dispensing, repeat dispensing, public health advice, signposting, disposal of unwanted medicines) are provided remotely only, via telephone, website, email, or other non-face-to-face channels.

- 1.28.2 A printed leaflet or notice will be available (and displayed at the entrance, where appropriate), explaining:

- 1.28.3 The distance-selling model

- 1.28.4 How patients can access our services remotely

- 1.28.5 Contact details for telephone and online support

1.29 No Service Provided at Premises

- 1.29.1 The patient will not be invited into the premises, nor will any essential service be provided in person.

- 1.29.2 No medicines, advice, or documentation will be dispensed, collected, or handed over on-site under any circumstances.

1.30 Supporting the Patient Remotely

- 1.30.1 The staff member may, if appropriate, offer to support the patient remotely by guiding them to contact us via telephone or online, so their query can be handled in accordance with our distance selling procedures.

1.31 Incident Logging and Review

- 1.31.1 All such occurrences will be logged in our internal records, including date, time, and summary of the situation.

- 1.31.2 Incidents will be reviewed periodically as part of our clinical governance and service assurance processes to ensure compliance with DSP requirements and to monitor for any trends in public misunderstanding or signage effectiveness.

1.32 Preventative Measures:

- 1.32.1 To minimise any such occurrences, the following preventative steps are in place:

- 1.32.2 Clear signage at all entry points stating that the pharmacy is not open to the public and that all services are provided remotely.
- 1.32.3 Patient-facing materials (website, EPS nomination confirmation emails, prescription labels) reiterate that this is a distance-selling pharmacy only.
- 1.32.4 Information on how to access all services is prominently displayed online and on delivery packaging inserts.
- 1.33 How Advanced Services Will Be Delivered from the Premises in Compliance with DSP Requirements:
- 1.34 Delivery by Staff in a Dedicated Area
 - 1.34.1 Advanced Services will be delivered by appropriately trained pharmacy staff, including registered pharmacists.
 - 1.34.2 All service delivery will take place in a dedicated consultation area, physically separate from the dispensary and from areas used for the provision of Essential Services. This ensures that Advanced Services are provided in a controlled, private, and uninterrupted environment, without disrupting the safe provision of Essential Services or breaching the DSP regulatory model.
- 1.35 No Face-to-Face Patient Interaction
 - 1.35.1 In accordance with DSP requirements, no face-to-face interaction with patients or their representatives will occur on the premises.
 - 1.35.2 All Advanced Services including Pharmacy First consultations and New Medicine Service (NMS) discussions will be conducted remotely, using telephone or secure video consultation platforms.
 - 1.35.3 Any clinical assessments, follow-ups, and advice will be completed without the patient visiting or accessing the pharmacy premises.
- 1.36 Use of Digital Tools and Remote Communication
 - 1.36.1 We use a combination of secure NHS digital platforms, structured consultation software Pharmaoutcomes and EPS to support remote service delivery.
 - 1.36.2 Patients are informed of their eligibility for Advanced Services through digital communications, printed leaflets sent with medication deliveries, and our pharmacy website.
 - 1.36.3 For Pharmacy First, appropriate clinical triage will be carried out remotely.
 - 1.36.4 Where in-person assessment is required, patients will be signposted to an alternative face-to-face NHS provider (e.g., a local community pharmacy or GP practice).

1.37 Staffing and Service Management

- 1.37.1 We have sufficient, trained staff on site to safely deliver both Essential and Advanced Services without overlap or disruption.
- 1.37.2 Staff roles and rotas clearly define time allocation for dispensing, clinical checking, and remote service delivery.
- 1.37.3 Pharmacists delivering Advanced Services are given dedicated time and space away from the dispensary to carry out consultations in line with clinical governance and service quality expectations.
- 1.37.4 While all Essential Services will continue to be delivered remotely only, in compliance with DSP requirements, Advanced Services (Pharmacy First and NMS) will be delivered by using secure remote communication methods.
- 1.37.5 These services will be carried out in a separate, private area, ensuring no face-to-face contact with patients and no disruption to essential service provision. Our procedures, infrastructure, and staffing all support safe, compliant, and high-quality service delivery under the Distance Selling Pharmacy model.”

2 Comments to the Commissioner

On reviewing the paperwork provided by PCSE, it was noted that the comments made by the Applicant to the representations on the application, had not been circulated or seen by parties.

In the interests of transparency and fairness, NHS Resolution sought to rely on the discretion afforded in paragraph 7 of Schedule 3 of the Regulations to vary the normal procedures and circulate these comments to parties for them to make observations on them if they so wished.

THE APPLICANT

2.1 “Rebuttal to Objections

2.2 We thank Community Pharmacy Greater Manchester (CPGM), Sterling Pharmacy, Well Pharmacy and Cohens Chemist for their submissions regarding our application. We welcome the opportunity to clarify and rebut the concerns raised.

2.3 Delivery of Essential Services, Controlled Drugs, Refrigerated Items, and Waste Collection (CPGM)

2.3.1 In line with Regulation 25(2), arrangements are in place to ensure uninterrupted provision of essential services to anyone in England during opening hours. Controlled Drugs and refrigerated medicines will be dispatched via trackable, temperature-controlled delivery partners. Waste medicines will be collected by a licensed national contractor, fully compliant with NHS and environmental standards. These measures guarantee safe and reliable access for patients at all times.

2.4 Remote-Only Model (CPGM & Sterling)

2.4.1 In line with Regulation 64 (DSP exemption), all services will be provided exclusively by remote means (telephone, video, digital).

2.4.2 The consultation room at the premises will be for staff use only (training, safeguarding, remote workstations). The premises are on the third floor of an office building with no lift and three flights of stairs, making walk-in access impractical and impossible. This acts as a natural safeguard against unintended face-to-face service provision. Signage and access controls reinforce that no patients may attend the premises.

2.5 Pharmacy First Service Delivery (CPGM)

2.5.1 All Pharmacy First consultations will be undertaken remotely. The only exception is acute otitis media, which requires otoscopy and therefore cannot be provided remotely. In such cases, patients will be signposted to a local provider able to deliver the service in line with NHS guidance. This ensures patient safety and maintains compliance with Pharmacy First requirements.

2.6 Local Need and Oversupply (Sterling)

2.6.1 The DSP framework is not based on local pharmaceutical needs assessments but on providing a comprehensive national service. Services are designed for patients across England who prefer or require remote access, not just the local Manchester population. Demand for digital consultations and home delivery has increased significantly, demonstrating that our service meets a distinct and growing patient preference.

2.7 Impact on High Street Pharmacies (Sterling)

2.7.1 Under Regulation 64, DSPs cannot operate shopfronts or supply services directly on the premises. Patients cannot attend in person, meaning our service is complementary, not competitive, with community pharmacies. By supporting digital-first patients, we reduce pressure on high-street providers.

2.8 Regulatory Compliance and Premises Suitability (Cohens)

2.8.1 The premises is already registered with the GPhC. No shop-front or direct patient services will operate, in accordance with Regulation 64. The location is not in or adjacent to another pharmacy or GP practice. Requirements of Regulation 25(2) and Regulation 64 are fully satisfied.

2.9 Patient Engagement (Sterling)

2.9.1 While DSPs are not required to demonstrate local need, the service model is based on national patient feedback from weight management, HRT, and long-term condition services, where secure remote access is valued. Regular patient satisfaction surveys will be conducted, with

anonymised data published to support transparency and continuous improvement.

2.10 Conclusion

2.10.1 The concerns raised are either fully addressed within our governance framework or not applicable to the DSP model.

2.10.2 Our premises (third floor office with no lift), service model, and contractual arrangements ensure there is no possibility of face-to-face provision, with full compliance with:

2.10.3 Regulation 25(2) – uninterrupted essential services

2.10.4 Regulation 64 – DSP exemption conditions (no shop-front, non-adjacency to other pharmacies/GPs, full range of services delivered remotely)

2.10.5 The premises is already registered with the GPhC, confirming governance and compliance.

2.10.6 We therefore respectfully request that our application be approved.

2.11 Regulations Compliance Summary

Regulation Requirement	Requirement Summary	How Kiag Medical Ltd Complies
Regulation 25(2)	Must ensure uninterrupted provision of essential services to anyone in England during opening hours.	Nationwide coverage with trackable, temperature controlled deliveries for Controlled Drugs and refrigerated medicines. Licensed national waste collection will be in place. SOPs ensure uninterrupted service during core and supplementary hours.
Regulation 64 (DSP Exemption)	DSPs must not supply services from a shop-front or allow direct patient access.	No walk-in service permitted. Premises are on the third floor, no lift, three flights of stairs, making face-to-face provision impossible. Clear signage and access controls reinforce DSP-only

		operation.
Regulation 64 (DSP Exemption)	Premises must be registered with the GPhC.	The premises is already registered with the GPhC.
Regulation 64 (DSP Exemption)	Premises must not be on the same or adjacent site to another pharmacy or GP practice.	Premises are not in the same or adjacent premises as any pharmacy or GP.
Regulation 64 (DSP Exemption)	Contractors must provide the full range of NHS pharmacy services remotely.	All services will be delivered remotely (telephone, video, digital). Pharmacy First provided remotely with the exception of acute otitis media, which requires otoscopy. Patients with suspected otitis media will be signposted to a local provider who can deliver the service."

2.12 [Photographs provided - see appendix A]

3 The Decision

The Commissioner considered and decided to refuse the application. The decision letter dated 31 December 2025 states:

[Any reference to 'Committee' in this section is not to be confused with the Pharmacy Appeals Committee of NHS Resolution]

- 3.1 "Greater Manchester ICB has considered the above application and I am writing to confirm that it has been refused. Please see the enclosed report for the full reasoning.
- 3.2 You have a right of appeal to the Secretary of State against Greater Manchester ICB's decision. Should you choose to appeal then you should either complete the online form available on the NHS Resolution website or send a concise and reasoned statement of the grounds for your appeal within 30 days of the date of this letter to nhsr.appeals@nhs.net or:
- 3.3 Primary Care Appeals, NHS Resolution, 8th Floor, 10 South Colonnade, Canary Wharf, London, E14 4PU"

Decision report

- 3.4 "Regulation 31 considerations

- 3.5 The PSRC to note the proposed location of the distance selling premises (DSP) is Office 2-3, 2nd Floor, 761 Wilmslow Road, Manchester, M20 6RN:
- 3.6 [Images, see Appendix B]
- 3.7 Clarification for the proposed address was requested on 27th October 2025 and below are the mages from the applicant's response:
- 3.8 [Image, see Appendix B]
- 3.9 The next nearest pharmacy to the proposed location is 407 feet away (source: the NHS Site) – Boots Pharmacy, 736-740 Wilmslow Road, Didsbury, Manchester, M20 2DW:
- 3.10 [Image, see Appendix B]
- 3.11 Based on all available information, the PSRC was satisfied that the application should not be refused under Regulation 31, as there is no other provider of pharmaceutical services either in the same premises or adjacent premises to the proposed location.
- 3.12 **Regulation 25 considerations**
- 3.13 **Are the premises listed in the application on the same site or in the same building as a provider of primary medical services with a patient list? (Regulation 25(2)(a))**
- 3.14 Based on all available information, the PSRC was satisfied that the proposed location is not on the same site or in the same building as a provider of primary medical services with a patient list.
- 3.15 **Will the applicant provide uninterrupted provision of essential services, during the opening hours of the premises, to persons anywhere in England who request those services? (Regulation 25(2)(b)(i)); and**
- 3.16 **Will the applicant ensure the safe and effective provision of essential services without face-to-face contact between any person receiving the services, whether on their own or on someone else's behalf, and the applicant or the applicant's staff? (Regulation 25(2)(b)(ii))**
- 3.17 The applicant has declared it will provide:
- 3.18 Core opening hours of 09:00-17:00 Monday to Friday and total opening hours 09:00-17:00 Monday to Friday
- 3.19 **3.1 Proposed core opening hours**

Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday	Total
09:00-17:00	09:00-17:00	09:00-17:00	09:00-17:00	09:00-17:00			40

3.20 3.2 Total proposed opening hours

Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday	Total
09:00-17:00	09:00-17:00	09:00-17:00	09:00-17:00	09:00-17:00			40

3.21 Proposed services:

Service	Accredited to provide (Y/N/NA)	Premises accredited(Y/N/NA)
Pharmacy First Service	Y	Y
New Medicine Service (NMS)	Y	Y

3.22 PSRC noted that a floor plan has been submitted: [see Appendix B]

3.23 The PSRC noted that the applicant had provided information in the application with regards to Regulation 25:

3.24 **The applicant has submitted the following information in support of their application:"**

3.25 [Page 6-8 and 10-15 of the application, please see above paragraph 1.2 to 1.37]

3.26 [SOPs provided from NMS, Pharmacy First and Remote Consultations in Community Pharmacy, these SOPs have been updated on Appeal]

3.27 "The application and the submitted information do not address comprehensively how the applicant aims to provide services without face-to-face contact and in uninterrupted manner.

3.28 Neither does it specify the operating procedures for handling cold chain deliveries, what happens in the event of unsuccessful deliveries, responsible pharmacist presence/absence, provision of NMS service, etc.

3.29 There is no floor plan included to ensure how the services would be delivered with no face-to-face contact.

3.30 **In light of the above, PSRC was not satisfied that the services will be provided in a safe and effective manner with no face-to-face contact in an uninterrupted manner.**

3.31 Therefore, the PSRC was not adequately assured that its procedures would enable the DSP to meet the requirements of Regulation 25(2), in addition to the ongoing requirements set out under Regulation 64 – which are:

- 3.31.1 that the applicant does not offer to provide pharmaceutical services, other than directed services, to persons who are present at (which includes in the vicinity of) the listed chemist premises;
- 3.31.2 that the means by which the applicant provides pharmaceutical services, other than directed services, must be such that any person receiving those services does so otherwise than at the listed chemist premises;
- 3.31.3 that the DSP must not be on the same site or in the same building as the premises of a provider of primary medical services with a patient list;
- 3.31.4 that the applicant secures the uninterrupted provision of essential services, during the opening hours of the premises, to persons anywhere in England who request those services,
- 3.31.5 that the applicant ensures the safe and effective provision of essential services without face-to-face contact between any person receiving the services, whether on their own or on someone else's behalf, and the applicant or applicant's staff; and
- 3.31.6 that nothing in the applicant's practice leaflet, publicity material in respect of the listed DSP, in material published on behalf of the applicant publicising services provided at or from the listed DSP or in any communication (written or oral) from the applicant or applicant's staff to any person seeking the provision of essential services from the applicant must represent, either expressly or impliedly, that the essential services provided at or from the premises are only available to persons in particular areas of England, or that the applicant is likely to refuse, for reasons other than those provided for in its terms of service, to provide drugs or appliances ordered on prescription forms or repeatable prescription forms which are presented by particular categories of patients (for example, because the availability of essential services from applicant is limited to other categories of patients).
- 3.32 The applicant is reminded that the commissioner (NHS GM) may not vary or remove any of the above conditions.
- 3.33 **The following interested parties within a 2km radius of the proposed premises location were notified of the application:**
- 3.34 **Interested parties notified of the application**

Boots	736-740 WILMSLOW ROAD	DIDSBURY	M20 2DW
DIDSBURY PHARMACY	676 WILMSLOW ROAD	DIDSBURY	M20 2DN
BARLOW PHARMACY	NHS CLINIC	828 WILMSLOW RD, DIDSBURY	M20 2RN

TESCO INSTORE PHARMACY	PARRS WOOD LANE	EAST DIDSBURY	M20 5NP
STERLING PHARMACY	103 LAPWING LANE	WEST DIDSBURY	M20 6UR
EVEREST PHARMACY DIDSBURY	2A LANE END ROAD	DIDSBURY	M19 1WA
COHENS CHEMIST	448 DIDSBURY ROAD	HEATON MERSEY	SK4 3BS
WELL	352-354 PALATINE ROAD	NORTHENDEN	M22 4HD
COHENS CHEMIST	THE NEW HEALTH CENTRE	56 BRIARFIELD ROAD	M20 4SS
WITHINGTON PHARMACY	8 COPSON STREET	WITHINGTON	M20 3HE
WILMSLOW PHARMACY WITHINGTON	480 WILMSLOW ROAD	WITHINGTON	M203BG
COHENS CHEMIST	62 WHITCHURCH ROAD	WITHINGTON	M20 1EY

3.35 Also informed were the following parties

3.35.1 CPGM

3.35.2 Manchester Local Medical Committee

3.35.3 Manchester HWB

3.35.4 Healthwatch Manchester

3.36 Representations received from interested parties

3.37 CPGM comment:

3.38 Re: Application for inclusion in a pharmaceutical list at Office 2-3, 2nd Floor, 761 Wilmslow Road, Manchester, M20 6RN by Kiag Medical Ltd

3.39 Thank you for your letter dated 31st July 2025 regarding the above application, and for the opportunity to submit representations.

3.40 The Community Pharmacy Greater Manchester (CPGM) applications subgroup requests clarification on off-site provision of services and notes that advanced and enhanced services should be delivered remotely or off-site where

permitted, rather than on the pharmacy premises. The application refers both to provision on-site in a consultation room and remote service provision.

- 3.41 For Pharmacy First, it is not appropriate to signpost patients to an alternative provider for a face-to-face assessment. Contractors must be able to deliver the full service themselves (with the exception of acute otitis media clinical pathway consultations).
- 3.42 While the route for new Distance Selling Pharmacy (DSP) applications has now closed under the updated regulatory framework, we acknowledge that this application was submitted prior to the deadline and is therefore eligible for consideration.
- 3.43 The 2023 report by the Company Chemists' Association (CCA) revealed that over 80% of DSPs primarily serve their local populations, in direct conflict with the requirement to provide a comprehensive, national service. Given the continued expansion of DSPs since that report, the extent of this issue is likely to have increased. If this application is approved, it is essential that NHS Greater Manchester implements rigorous monitoring processes to ensure the applicant fully complies with all contractual obligations, Community Pharmacy Greater Manchester greatermanchester.communitypharmacy.org.uk
- 3.44 particularly in delivering a national service and the appropriate provision of both core and supplementary hours.
- 3.45 Following a detailed review by the Applications Subgroup of Community Pharmacy Greater Manchester (CPGM), we are of the view that the NHSCB must ensure that the applicant has clearly demonstrated compliance with Regulation 25(2) of the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. Specifically, this includes:
 - 3.46 Ensuring the uninterrupted provision of essential services during opening hours to anyone in England who requests them. We are especially concerned about whether suitable arrangements are in place for the delivery of Controlled Drugs (CDs) and refrigerated items at all times, as well as the collection of waste medicines from patients.
 - 3.47 Guaranteeing the safe and effective delivery of essential and advanced services without any face-to-face contact between service users (or their representatives) and the pharmacy team.
 - 3.48 CPGM would welcome continued communication on the progress of this application and request that we are kept informed of any developments."
- 3.49 **Cohens Pharmacy comment:**
- 3.50 Thank you for sending the above application dated 31 July 2025
- 3.51 We wish to make the following comments – We would like to be assured that the PCSE takes into account all criteria relating to regulation 25 and the conditions set out in regulation 64 as part the Exemption for an Internet Pharmacy including –

- 3.51.1 They must provide the full range of NHS pharmacy services, including all essential services
- 3.51.2 These services must not be supplied from a traditional 'shop-front' premises – there should be no direct services to customers/patients on the premises
- 3.51.3 The premises should also be registered with the GPhC
- 3.51.4 That there are no LPS sites which would prohibit this exemption application
- 3.51.5 The location is not in the same or adjacent premises to an existing pharmacy or General Practitioner
- 3.52 We are sure that NHS England will have regard for these points when considering this.
- 3.53 **Well Pharmacy comment:**
- 3.54 Thank you for informing Well of the above application and for inviting written representations. We are willing to attend an oral hearing if the Area Team deem it necessary to hold one.
- 3.55 The ICB must be assured that this application fully satisfies Regulation 25 and Regulation 64 of the NHS (Pharmaceutical Services) Regulations 2013 before it should be granted.
- 3.56 The ICB should have regard to regulation 25(2) which states that the NHSCB must refuse the application unless it is satisfied that the procedures of the proposed pharmacy premises will allow for the uninterrupted provision of essential services during the opening hours stated on the application form from anywhere in England. Furthermore, the safe and effective provision of essential services must be assured without face-to-face contact with the patient or the patient's representative.
- 3.57 Well respectfully draw the ICB's attention to the fact that this application should not be approved automatically. To approve an application under the "distance selling premises" exemption, the application must wholly satisfy the Regulations rather than partially satisfying them.
- 3.58 Manchester HWB:
- 3.59 Thank you for your letter dated 31st July 2025, informing us of the above application and inviting Manchester Health and Wellbeing Board to make representations.
- 3.60 Manchester Health and Wellbeing Board has reviewed this application and is of the opinion that the PSRC must ensure that the applicant has satisfied Regulation 25(2) of the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 by fully explaining how the pharmacy procedures will secure the safe and effective provision of essential services without face to

face contact between any person receiving the services, whether on their own behalf or on behalf of someone else, and the applicant or the applicant's staff.

3.61 **Sterling Pharmacy comment/objection:**

3.62 "Dear Sir/Madam,

3.63 I am writing on behalf of Sterling Pharmacy (103 Lapwing Lane, Didsbury, M20 6UR) to formally object to the application by Kiag Medical Limited for a Distance Selling Pharmacy (DSP) near our location (Reference: CAS-370821-Z6N0V5), as notified via the 45-day letter dated 31 July 2025.

3.64 Existing Robust Local Provision

3.65 Sterling Pharmacy already incorporates Independent Prescribers (IPs) within the branch, offering advanced clinical services such as:

3.65.1 Pharmacy First

3.65.2 New Medicine Service (NMS)

3.65.3 Remote consultations

3.65.4 Contraceptive services

3.66 These services are delivered with a high standard of clinical oversight and continuity of care. The proposed DSP would operate in an area that is already well served, with more than sufficient pharmacy coverage, meaning the application offers no additional benefit to local patients.

3.67 Risk of Undermining Local High-Street Pharmacy

3.68 Allowing another provider—even via the DSP route—threatens the financial sustainability of existing community pharmacies.

3.69 Our pharmacy supports the NHS with:

3.69.1 Accessible over-the-counter care

3.69.2 Face-to-face clinical services

3.69.3 Timely dispensing of acute medications

3.70 Adding a DSP into this well-covered locality places unnecessary pressure on already stretched providers, undermining service stability and reducing community resilience.

3.71 Lack of Clarity on Remote-Only Operation & SOP Deficiencies

3.72 The submitted SOPs for remote consultations, NMS, and Pharmacy First fail to demonstrate a strictly remote model and do not contain sufficient operational safeguards to prevent unintended walk-in activity.

- 3.73 Additionally, the applicant's "How we will involve patients..." document lacks evidence of meaningful local patient engagement.
- 3.74 There is no transparency on how the service will actively avoid physical interactions, raising concern that the DSP may resemble a walk-in or hybrid model—contrary to the regulatory requirements.
- 3.75 Policy & Purpose Misuse
- 3.76 The DSP model was created to extend access to pharmacy services in underserved or rural populations where local options do not exist.
- 3.77 Establishing a DSP in a densely served urban postcode like M20 6RN circumvents the policy's purpose, and risks undermining the intended function of the framework.
- 3.78 Approving such applications distorts the DSP scheme and creates unfair competitive risk to community-based pharmacies like ours, who operate under different financial and compliance pressures.
- 3.79 Local Regulatory & Economic Considerations
- 3.80 The application does not reference any:
- 3.80.1 Local pharmaceutical needs assessment
 - 3.80.2 Service utilisation data (e.g., MURs, Pharmacy First figures)
 - 3.80.3 Unmet demand metrics
- 3.81 This lack of context diminishes NHS England's ability to evaluate the local relevance or necessity of the application.
- 3.82 We respectfully request NHS England to reject this application, on the grounds that it provides no incremental benefit, and poses a detrimental impact on existing pharmaceutical services in the area.
- 3.83 If NHS England does not proceed with immediate rejection, we ask that the applicant be required to submit a local impact assessment, including:
- 3.83.1 Measurable evidence of unmet local need
 - 3.83.2 Engagement with local patients
 - 3.83.3 Concrete safeguards preventing unintended in-person service provision
- 3.84 Please confirm receipt of this objection and advise on any further documentation NHS England requires from our side".
- 3.85 **Representations received outside the 45 day notification period: None**
- 3.86 **Representations received from circulation of first representations:**

3.87 **Applicant's response:**

3.88 "Re: Application for inclusion in a pharmaceutical list – Distance Selling Pharmacy Reference: CAS-370821-Z6N0V5

3.89 Rebuttal to Objections

3.90 Dear Naheem,

3.91 We thank Community Pharmacy Greater Manchester (CPGM), Sterling Pharmacy, Well Pharmacy and Cohens Chemist for their submissions regarding our application. We welcome the opportunity to clarify and rebut the concerns raised.

3.92 Delivery of Essential Services, Controlled Drugs, Refrigerated Items, and Waste Collection (CPGM)

3.93 In line with Regulation 25(2), arrangements are in place to ensure uninterrupted provision of essential services to anyone in England during opening hours. Controlled Drugs and refrigerated medicines will be dispatched via trackable, temperature-controlled delivery partners. Waste medicines will be collected by a licensed national contractor, fully compliant with NHS and environmental standards. These measures guarantee safe and reliable access for patients at all times.

3.94 Remote-Only Model (CPGM & Sterling)

3.95 In line with Regulation 64 (DSP exemption), all services will be provided exclusively by remote means (telephone, video, digital).

3.96 The consultation room at the premises will be for staff use only (training, safeguarding, remote workstations). The premises are on the third floor of an office building with no lift and three flights of stairs, making walk-in access impractical and impossible. This acts as a natural safeguard against unintended face-to-face service provision. Signage and access controls reinforce that no patients may attend the premises.

3.97 Pharmacy First Service Delivery (CPGM)

3.98 All Pharmacy First consultations will be undertaken remotely. The only exception is acute otitis media, which requires otoscopy and therefore cannot be provided remotely. In such cases, patients will be signposted to a local provider able to deliver the service in line with NHS guidance. This ensures patient safety and maintains compliance with Pharmacy First requirements.

3.99 Local Need and Oversupply (Sterling)

3.100 The DSP framework is not based on local pharmaceutical needs assessments but on providing a comprehensive national service. Services are designed for patients across England who prefer or require remote access, not just the local Manchester population. Demand for digital consultations and home delivery has increased significantly, demonstrating that our service meets a distinct and growing patient preference.

- 3.101 Impact on High Street Pharmacies (Sterling)
- 3.102 Under Regulation 64, DSPs cannot operate shopfronts or supply services directly on the premises. Patients cannot attend in person, meaning our service is complementary, not competitive, with community pharmacies. By supporting digital-first patients, we reduce pressure on high-street providers.
- 3.103 Regulatory Compliance and Premises Suitability (Cohens)
- 3.104 The premises is already registered with the GPhC. No shop-front or direct patient services will operate, in accordance with Regulation 64. The location is not in or adjacent to another pharmacy or GP practice. Requirements of Regulation 25(2) and Regulation 64 are fully satisfied.
- 3.105 Patient Engagement (Sterling)
- 3.106 While DSPs are not required to demonstrate local need, the service model is based on national patient feedback from weight management, HRT, and long-term condition services, where secure remote access is valued. Regular patient satisfaction surveys will be conducted, with anonymised data published to support transparency and continuous improvement.
- 3.107 Conclusion
- 3.108 The concerns raised are either fully addressed within our governance framework or not applicable to the DSP model. Our premises (third floor office with no lift), service model, and contractual arrangements ensure there is no possibility of face-to-face provision, with full compliance with:
- 3.109 Regulation 25(2) – uninterrupted essential services Regulation 64 – DSP exemption conditions (no shop-front, non-adjacency to other pharmacies/GPs, full range of services delivered remotely) The premises is already registered with the GPhC, confirming governance and compliance. We therefore respectfully request that our application be approved”.
- 3.110 The PSRC reviewed the representations and was not satisfied that it meets all the requirements of Regulation 25(2)(b), in addition to the ongoing requirements set out under Regulation 64.
- 3.111 **The PSRC determined the application does not meet the requirements of Regulation 25(2)(b)(i) and Regulation 25(2)(b)(ii).**
- 3.112 The PSRC to also consider the impact of decision on those with protected characteristics under the Equalities Act 2010, in accordance with NHS England/ICB's Public Sector Equality Duty and its duties on health inequality.
- 3.113 It was noted that from 01/01/2021 for all face-to-face community pharmacies (and 01/04/2021 for all distance selling premises), the system of clinical governance within the Terms of Service was expanded to include the promotion of healthy living. The Healthy Living Pharmacy (HLP) framework is aimed at achieving consistent provision of a broad range of health promotion interventions through community pharmacies to meet local need, improving the health and wellbeing of the local population and helping to reduce health

inequalities. NHS Greater Manchester is committed to support its community pharmacies in achieving and maintaining compliance with this framework.

3.114 Decision

3.115 Based on all available information, the PSRC refused the application, as it concluded that the application did not meet the requirements of Regulation 25(2)(b)(i) and Regulation 25(2)(b)(ii).

3.116 Appeal rights are awarded to the applicant.

3.117 The Pharmaceutical Services Regulations Committee (PSRC) makes decisions on applications made under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, as amended.

3.118 The above decision does not, at this point, constitute a contractual change. However, should the applicant commence pharmaceutical services following this grant, its inclusion in the Pharmaceutical List as a new contractor would constitute a contractual change.”

4 The Appeal

In a letter dated 23 January 2026, Rushport Advisory LLP on behalf of the Applicant appealed against the Commissioner’s decision. The grounds of appeal are:

4.1 “I act for KIAG MEDICAL LTD and have been instructed by my client to submit this appeal against the attached decision of the Commissioner to refuse the above application.

4.2 The Commissioner’s reason for refusing my client’s application is stated as.

4.3 *“The application and the submitted information do not address comprehensively how the applicant aims to provide services without face-to-face contact and in uninterrupted manner. Neither does it specify the operating procedures for handling cold chain deliveries, what happens in the event of unsuccessful deliveries, responsible pharmacist presence/absence, provision of NMS service, etc. There is no floor plan included to ensure how the services would be delivered with no face-to-face contact.”*

4.4 The premises floor plan has been included with this appeal. The premises are self-contained with a controlled entry system and patients cannot access the premises for any NHS service.

4.5 The premises has already been approved by the GPhC with premises number 9012762.

4.6 In addition, my client has instructed me to submit the attached SOPs that have been approved by my client for use at the proposed pharmacy and address each of the points raised by the Commissioner as well as all other parts of regulation 25. We trust that these provide the Committee with sufficient detail to allow the appeal. These SOPs are updated from the SOPs that my client submitted with its original application and the previous version of the SOPs should now be disregarded.

4.7 We look forward to hearing from you in due course.”

4.8 [SOPs provided, see Appendix C]

5 **Summary of Representations**

No representations were received in response to the appeal.

6 **Consideration**

6.1 The Pharmacy Appeals Committee (“Committee”) appointed by NHS Resolution, had before it the papers considered by the Commissioner.

6.2 It also had before it the responses to NHS Resolution’s own statutory consultations.

6.3 On the basis of this information, the Committee considered it was not necessary to hold an Oral Hearing.

6.4 The Committee had regard to the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 (“the Regulations”).

Regulation 31

6.5 The Committee first considered Regulation 31 of the Regulations which states:

(1) A routine or excepted application, other than a consolidation application, must be refused where paragraph (2) applies.

(2) This paragraph applies where -

(a) a person on the pharmaceutical list (which may or may not be the applicant) is providing or has undertaken to provide pharmaceutical services (“the existing services”) at or from -

(i) the premises to which the application relates, or

(ii) adjacent premises; and

(b) NHS England is satisfied that it is reasonable to treat the services that the applicant proposes to provide as part of the same service as the existing services (and so the premises to which the application relates and the existing listed chemist premises should be treated as the same site).

6.6 The Committee noted the Applicant’s comments in the relevant section in the application form appear to misunderstand the test. The Applicant refers to why it intends on providing services rather than the proposed premises being adjacent to or in close proximity to, another pharmacy or dispensing appliance contractor premises.

- 6.7 The Commissioner had concluded that it was “*satisfied that the application should not be refused under Regulation 31*” and that this had not been disputed either on appeal or in subsequent representations.
- 6.8 The Committee therefore determined that it was not required to refuse the application under the provisions of Regulation 31.

Regulation 25

- 6.9 The Committee had regard to Regulation 25 of the Regulations which reads as follows:

- “(1) *Section 129(2A) and (2B) of the 2006 Act (regulations as to pharmaceutical services) does not apply to an application—*
- (a) for inclusion in a pharmaceutical list by a person not already included; or*
 - (b) by a person already included in a pharmaceutical list for inclusion in that list in respect of premises other than those already listed in relation to that person,*
- in respect of pharmacy premises that are distance selling premises.*
- (2) *NHS England must refuse an application to which paragraph (1) applies—*
- (a) if the premises in respect of which the application is made are on the same site or in the same building as the premises of a provider of primary medical services with a patient list; and*
 - (b) unless NHS England is satisfied that the pharmacy procedures for the pharmacy premises are likely to secure—*
 - (i) the uninterrupted provision of essential services, during the opening hours of the premises, to persons anywhere in England who request those services, and*
 - (ii) the safe and effective provision of pharmaceutical services without face to face contact at the pharmacy premises between any person receiving the services, whether on their own or on someone else’s behalf, and the applicant or the applicant’s staff.”*

- 6.10 The Committee also had regard to the provisions of Schedule 2 to the Regulations shown below:

Additional information to be included with excepted applications

8. *If the applicant (A) is making an excepted application, A must include in that application details that explain—*

- (a) *A's belief that the application satisfies the criteria included in one of the regulations in Part 4 which need to be satisfied if section 129(2A) and (2B) of the 2006 Act (regulations as to pharmaceutical services) are not to apply in relation to that application; and*
- (b) *if the regulation includes reasons for which the application must be refused, why the application should not be refused for those reasons.*

Nature of details to be supplied

- 10. *Where, pursuant to this Part, a person is required to provide details, that obligation is only discharged if the information or documentation provided is sufficient to satisfy NHS England in receipt of it, with good cause, that no relevant information or documentation is missing, having regard to the uses that NHS England may need to make of the information or documentation when carrying out its functions.*

Regulation 25(1)

- 6.11 In relation to Regulation 25(1), the Applicant is applying for inclusion in the relevant pharmaceutical list, as a person not already included in a pharmaceutical list, and paragraph (1)(a) therefore operates to disapply the specified provisions of section 129 of the National Health Service Act 2006, provided that paragraph (2) does not require the application to be refused.

Regulation 25(2)(a)

- 6.12 The Committee noted that the Applicant had not included any information in the relevant section of the application form that deals with this point. The Committee noted that the application form states that the relevant section should only be completed if the proposed premises are on the same site or in the same building as the premises of a provider of primary medical services with a patient list. The Committee considered that, where the Applicant did not include any information in this section, it was reasonable to consider that the Applicant was indicating that the proposed premises were not on the same site or in the same building as the premises of a provider of primary medical services with a patient list. The Commissioner in its decision report stated that it "...was satisfied that the proposed location is not on the same site or in the same building as a provider of primary medical services with a patient list". Based on the information available to it, which had not been disputed, the Committee therefore determined that the proposed premises were not on the same site as, or in the same building as the premises of a provider of primary medical services with a patient list.

Regulation 25(2)(b)

- 6.13 As far as Regulation 25(2)(b) is concerned, the Committee considered the information which had been provided by the Applicant in relation to its procedures for the provision of essential services and pharmaceutical services, including its Standard Operating Procedures (SOPs) that it intends to use at the proposed pharmacy premises.

- 6.14 The Regulations require the Committee to be satisfied as to a number of matters, including that essential services will be provided on an uninterrupted basis, across England, and that pharmaceutical services will be provided in a safe and effective way without face to face contact.
- 6.15 Paragraph 8 of Schedule 2 requires an applicant to provide details in relation to an application, and paragraph 10 of Schedule 2 indicates that the obligation is only discharged if the information or documentation provided is sufficient to satisfy the Commissioner in receipt of it, with good cause, that no relevant information or documentation is missing, having regard to the uses that the Commissioner may need to make of the information or documentation when carrying out its functions.
- 6.16 The Committee has asked itself whether it has sufficient information and documentation which would address the criteria in Regulation 25(2)(b). If the Committee is to be satisfied of the matters in that paragraph, the Committee must be provided with evidence to demonstrate these matters. In this case, that evidence put forward has taken the form of updated SOPs which the Applicant has prepared or commissioned.
- 6.17 It is not for the Committee to 'approve' or 'disapprove' of these SOPs (as they may contain matters not relevant to the Committee's consideration, and there are many ways an applicant can choose to organise itself in order to comply with the various requirements of the Regulations) and the Committee has not sought to do so. The Committee has sought evidence within the updated SOPs in order to satisfy itself that it is appropriate to grant the application, the absence of which would require it to reject it.
- 6.18 The Committee first considered how the Applicant would provide essential services without interruption and noted the following information in the Applicant's SOPs:
- 6.19 SOP 1: *"Introduction and Background to SOPs"*
- 6.19.1 *"1.3 Overriding Provisions Applicable to All SOPs"*
- The uninterrupted provision of pharmaceutical services, during the opening hours of the premises, to persons anywhere in England who request those services.*
- The safe and effective provision of pharmaceutical services without face-to-face contact between any person receiving the services, whether on their own or on someone else's behalf, and the owner of this pharmacy or any member of staff either on or in the vicinity of the premises."*
- 6.20 SOP 33: *"The Responsible Pharmacist"*
- 6.20.1 *"33.9 Absence of the RP"*
- As a Distance Selling pharmacy, we must provide uninterrupted service throughout the opening hours of the pharmacy. Whilst the GPhC permits the absence of the RP from the pharmacy in particular*

situations, the NHS Terms of Service still require a pharmacist to be present so that services are not interrupted. [Applicant's emphasis]

If, for any reason, the RP wishes to leave the premises or wishes to take a break then the second pharmacist must sign in as the RP and arrangements must be made for this prior to one RP leaving the premises and another RP signing in."

6.21 Based on the information before it, the Committee was of the view that the provision of essential services would be without interruption.

6.22 With regard to essential services being available to persons anywhere in England, the Committee noted the following information in the Applicant's SOPs:

6.23 SOP 1: *"Introduction and Background to SOPs"*

6.23.1 *"1.3 Overriding Provisions Applicable to All SOPs"*

"In order to comply with our terms of service, this pharmacy will provide;

The uninterrupted provision of pharmaceutical services, during the opening hours of the premises, to persons anywhere in England who request those services"

6.24 SOP 3: *"Procedures for NHS Pharmaceutical Services"*

6.24.1 *"NHS Pharmaceutical Services will be provided to any patient living in England who requests such services, this is made clear on the website and in the Practice leaflet."*

6.25 As well as the assertions in the "overriding provisions" in SOP 1, as set out above with regard to pharmaceutical services being available to patients anywhere in England, the Committee noted references throughout the rest of the SOPs to delivery being made by couriers and Royal Mail as well as the Applicant's own delivery driver.

6.26 The Committee was of the view, based on all of the information before it, that the essential services would be provided to persons anywhere in England, who requested those services.

6.27 The Committee next considered how the Applicant would provide pharmaceutical services without face to face contact. The Committee noted that in its decision report the Commissioner had stated *"The application and the submitted information do not address comprehensively how the applicant aims to provide services without face-to-face contact and in uninterrupted manner"* which had led the Commissioner to the conclusion that it *"was not satisfied that the services will be provided in a safe and effective manner with no face-to-face contact in an uninterrupted manner."*

6.28 The Commissioner had further stated *"There is no floor plan included to ensure how the services would be delivered with no face-to-face contact"*. The Committee noted that, on appeal, the Applicant's representative had provided

a floor plan and the Committee also had regard to the photographs as provided in the Commissioner's decision letter.

6.29 The Committee also noted the following information in the Applicant's SOPs:

6.30 SOP 1: *"Introduction and Background to SOPs"*

6.30.1 *"1.3 Overriding Provisions Applicable to All SOPs"*

6.30.2 *In order to comply with our terms of service, this pharmacy will provide;*

...The safe and effective provision of pharmaceutical services without face-to-face contact between any person receiving the services, whether on their own or on someone else's behalf, and the owner of this pharmacy or any member of staff either on or in the vicinity of the premises.

... All staff must be made aware that face to face contact between patients (or their representatives) is prohibited in respect of any and all NHS services either on or in the vicinity of the premises.

Any reference to 'contact' with or 'contacting' a patient in relation to these SOPs means contact other than face-to-face contact either on or in the vicinity of the premises."

6.31 SOP 3: *"Procedures for NHS Pharmaceutical Services"*

6.31.1 *"3.1 Communication Channels"*

All communication regarding NHS Pharmaceutical Services should be carried out using the most suitable non face to face method for the patient and the service being provided with particular consideration to maintaining confidentiality. This may be telephone, email, video-conferencing or other types of non face to face communications such as text messages."

"The pharmacy has provision for both live audio and live video communication with patients and this must always be carried out in the specified confidential area of the pharmacy premises."

6.31.2 *"3.2 Request for face-to-face service provision"*

OUR PHARMACY OPERATES FROM SELF-CONTAINED PREMISES THAT USE A CONTROLLED ACCESS SYSTEM. MEMBERS OF THE PUBLIC ARE NOT ABLE TO ATTEND THE PREMISES TO RECEIVE ANY NHS SERVICES [Applicant's emphasis]

If any member of staff receives a query from any member of the public, or patient or their carers that requests the provision of any pharmaceutical service face to face on or in the vicinity of the premises then they must;

Inform the person that, we cannot provide any face to face NHS services

Refer the person to the Responsible Pharmacist if they require any further explanation.”

- 6.32 The Committee was of the view that there was nothing provided in the information submitted by the Applicant, including the floor plan and photographs of the premises, which demonstrated that pharmaceutical services would be provided by face to face contact at, or in the vicinity of, the pharmacy premises.
- 6.33 The Committee was mindful of the regulatory changes as of 1 October 2025 and 31 March 2026, that distance selling pharmacies can no longer provide Directed services (Advanced, National Enhanced and Enhanced Services) face to face with the patient at the pharmacy premises. As a result of this amendment, the Committee noted that the Applicant would not be able to provide any pharmaceutical services to patients present at its premises.
- 6.34 In its application the Applicant stated that it did not intend to provide any advanced services. However, the Applicant’s updated SOP 3.3 states “NMS will be conducted remotely with no patients accessing the service at the premises (see NMS SOP). Pharmacy First will be provided remotely if the pharmacy has been approved to provide the service”. The Committee had regard to the relevant SOPs.
- 6.35 The Committee noted SOP 7 ‘The New Medicine Service (“NMS”)’ which states “The service must be provided remotely by phone or video call” and also noted SOP 8 ‘The Pharmacy First Service’ which states:

6.35.1 *“THIS SOP IS INCLUDED IN OUR SUITE OF SOPS HOWEVER THE SERVICE MAY ONLY BE PROVIDED IF APPROVAL FOR IT HAS BEEN OBTAINED FROM THE ICB AND THE PHARMACIST HAS COMPLETED THE REQUIRED TRAINING ON THE SERVICE*

...

Service Limitations

As a DSP we are permitted to provide the Pharmacy First Service subject to the following conditions and requirements.

The pharmacy must be approved to provide the service

The pharmacist and any staff involved in providing the service must have completed the required training.

Unlike pharmacies that are not DSPs – we are not permitted to undertake the “Acute Otitis Media” Clinical Pathway

Patients may not attend the premises to receive the service and the service must be provided remotely”

- 6.36 The Committee was aware that if the pharmacy opens, it will be the responsibility of the Commissioner, in keeping with Regulation 64, to ensure that services are provided other than with face to face contact.
- 6.37 The Committee was satisfied that the provision of essential services would be without interruption and would be available to persons anywhere in England and pharmaceutical services would be provided without face to face contact. The Committee went on to consider whether the safe and effective provision of pharmaceutical services was likely to be secured.
- 6.38 The Committee considered pharmaceutical services including each essential service in paragraphs 3 to 22 of schedule 4 of the Regulations ("Terms of Service") in turn.

Dispensing of drugs and appliances

- 6.39 The Committee considered whether the Applicant had explained how non-electronic prescriptions will be presented by the patient and how products will be provided.
- 6.40 The Committee noted SOP 3 'Procedures for NHS Pharmaceutical Services' states:
- 6.40.1 *"...Patients who wish to send paper prescriptions to the pharmacy by post should be sent stamped addressed envelopes to enable them to do so."*
- 6.41 SOP 6 'Prescription Receipt & Exemption Checking' states:
- 6.41.1 "6.2 Scope
- All online services including the following:*
- ... NHS Prescriptions."*
- 6.41.2 "6.7 Administration Checks
- 6.41.3 *Check all prescriptions received in the post against printed and written prescription reception forms. Check the corresponding prescription has been received in the post..."*
- 6.42 SOP 19 'Order Delivery' states:
- 6.42.1 "19.6 Choice of Delivery Method
- For items other than cold chain / "fridge line" items, local deliveries (up to 30 miles radius, but may be extended at the discretion of the RP) the delivery driver should deliver medication. Outside this area Royal Mail should be used unless the prescription is for a controlled drug, in which case the nominated controlled drugs courier must be used (see SOP for Delivery of Controlled Drugs), or the items are fridge lines, in which case the cold chain courier must be used (see below)." [Applicant's emphasis].*

- 6.43 The Committee was satisfied as to how patients throughout England would present their prescriptions and that the Applicant was proposing to offer products and services to all of England, as per the information contained in the SOPs.
- 6.44 The Committee was therefore satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 5(2) and 5(3) of Schedule 4.

Urgent supply without a prescription

- 6.45 The Committee considered whether the Applicant had explained how it proposes to safely and effectively receive requests from prescribers for urgent supplies of drugs and appliances.
- 6.46 The Committee noted the information in the Applicant's SOPs under the heading 'Emergency Supply and Urgent Supply' (SOP 16) which describes how the Applicant will process such a request. The Committee noted that the SOPs refer to pharmaceutical services being delivered by several means of non-face to face communication including telephone and email, and considered that it was reasonable to infer that these methods would be used to receive requests from prescribers for the urgent supply of drugs.
- 6.47 The Committee was therefore satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 6 of Schedule 4.

Preliminary matters before providing ordered drugs or appliances

- 6.48 The Committee considered whether the Applicant had explained how evidence will be sought and provided about the patients' entitlement to exemption or remissions from NHS Charges.
- 6.49 The Committee noted SOP 6 'Prescription Receipt & Exemption Checking states:

6.49.1 "6.9 Exempt NHS Prescriptions

...

Where evidence of exemption is required or provided by the patient it can be sent to the pharmacy for verification via the delivery driver and then returned to the patient. The PMR system should be updated to reflect that necessary check has been carried out and a note of when the next check is required should be entered onto the system. The Regulations require a patient to produce 'satisfactory evidence' to confirm exemption. Where appropriate (i.e., for deliveries made other than by the pharmacy's delivery driver), the patient may scan or fax copies of the evidence to the pharmacy (or use the postal / courier service, but see NOTE below) and the pharmacy can note that the evidence provided was not in original format. It is for the pharmacist in charge to determine if the evidence is satisfactory or not and, if not, then cross the 'Evidence not Seen' box."

6.50 The Committee was therefore satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 7(3) of Schedule 4.

6.51 The Committee considered whether the Applicant had explained how charges will be paid.

6.52 The Committee noted SOP 6 'Prescription Receipt & Exemption Checking' states:

6.52.1 "6.12 Paid NHS Prescription

Check the prescription to confirm how many charges are due.

Check to see if any fees have been paid and if so, was the correct amount paid?

Contact the patient to arrange payment using the secure payments system using the "customer not present" option.

If no fees have been paid or there is a discrepancy between fees paid and those due, the patient should be contacted and directed to pay the appropriate fees via the online payment system."

6.53 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 7(5)(b) of Schedule 4.

Providing ordered drugs or appliances

6.54 The Committee considered whether the Applicant had explained how drugs/appliances will be provided to the patient (including to ensure that (i) the 'cold chain' is maintained, where relevant, and (ii) that the requirements of the Misuse of Drugs Regulations 2001 and, in particular, Regulations 14 and 16, are met).

6.55 The Committee noted that the Commissioner was of the view that "*The application and the submitted information do not address comprehensively how the applicant aims to provide services without face-to-face contact and in uninterrupted manner.*

Neither does it specify the operating procedures for handling cold chain deliveries, what happens in the event of unsuccessful deliveries, responsible pharmacist presence/absence, provision of NMS service, etc".

6.56 The Committee noted in its SOPs provided on appeal, in particular SOP 19 'Order Delivery' which states:

6.56.1 "19.10 Transfer to the Delivery Driver

Ensure that the pharmacist on duty is available to supervise the handing over of all items for delivery.

Ensure that any special instructions for the delivery are included with the packaging.

Ask the delivery driver to check the details on the delivery sheet correspond to the deliveries.

Ensure the delivery driver completes all the sections on the delivery sheet including their name and the date.

Ensure the delivery driver is notified of any messages for the patient or representative.

Make and retain a copy of the delivery sheet until the original has been returned by the delivery driver. The original must be returned to the pharmacy on the same day.

Ensure the deliveries are placed in the delivery vehicle and are stored securely and out of sight. The delivery vehicle must be locked at all times when left unattended.

At hand-over to the driver / courier ensure that any current falsified medicines regulation or guidance is followed.”

6.56.2 “19.11 Delivery of prescription to patient or representative address

Ask the patient/representative for their name and address.

Check the patient name and address against the prescription and the bag label. Patient confidentiality should be maintained at all times, especially if delivering to a representative.

Where appropriate ask the patient or representative to complete the reverse of the prescription.

Hand the medication to the patient or representative.

Ask the patient or representative to sign their details on the delivery sheet. If they are unable to sign the delivery sheet the delivery driver should sign on their behalf with their consent and write a note explaining the reason the patient or representative could not sign.

If necessary, collect any medication returns. Always use the Patient Returned Medication Tray that is available in the delivery vehicle. Refer to the Patient Returned Medicines SOP for further guidance.”

6.56.3 “19.12 Successful delivery

6.56.4 *Once the deliveries are completed, return the delivery sheets to the pharmacy on the same day. The delivery sheets must be scanned into the pharmacy IT system and kept for a minimum period of 7 years.”*

6.56.5 “19.13 Unsuccessful Delivery

If the patient or representative is not able to receive the delivery of their medication, complete the 'attempted delivery' form and post it through the letterbox. The form will have details for arranging re-delivery.

The prescription and medication must be returned to the pharmacy on the same day and the pharmacist informed of the unsuccessful delivery.

The pharmacy must follow up the unsuccessful delivery by contacting the patient to arrange a second delivery time.

DO NOT:

Post the medication through the letter/post box.

Leave the medication in the porch or any other out building.

Leave the medication at an unauthorised address."

6.56.6 "19.14 Delivery of a prescription via Royal Mail (Not for Cold Chain or CDs)

Follow preparation for delivery process. The pharmacist must contact any patients for whom there are relevant messages or counselling required.

Ensure that the pharmacist on duty is available to supervise the handing over of all items for delivery.

Print and attach relevant Royal Mail Signed For delivery labels using the Royal Mail online business account and attach securely to outer packaging.

Ensure a return address is printed clearly on the outer packaging.

Confirm details of all prescriptions to be delivered.

Make a note of all Tracking numbers for prescriptions being delivered by Royal Mail on Delivery Log sheet.

Ensure Royal Mail driver signs Delivery Log sheet for all prescriptions being accepted for delivery. The delivery sheets must be scanned into the pharmacy IT system and kept for a minimum period of 7 years.

Email patients dispatch confirmation with their Tracking number when the prescriptions have left the premises.

All deliveries will require a signature from the patient to confirm receipt of their prescription."

6.56.7 "19.15 Unsuccessful Delivery via Royal Mail

In the event of an unsuccessful delivery, Royal Mail will leave a 'Sorry We Missed You' card, stating the date and time of the attempted

delivery. The patient can then either choose to collect and sign for their medicines at their local post office, or rearrange delivery for a convenient time by telephone or email.”

6.56.8 “19.16 Cold chain delivery via courier

All cold chain deliveries must be carried out by couriers with verified and approved cold chain procedures. A list of approved cold chain couriers is available within the Pharmacy and will be updated from time to time. Each approved courier meets stringent criteria to ensure a fully monitored and dedicated cold chain service.

Specialist cold chain courier service will ensure the integrity of the cold chain and the maximum stability of thermo-labile drugs by packing, transporting and delivering in such a way that their integrity, quality and effectiveness are always preserved. This is a dedicated, fully monitored and temperature controlled delivery service.

Any breach of cold chain conditions will be notified to the driver and any affected delivery will be cancelled with the pharmacy informed of the cold chain breach.

...Ensure any items for cold chain delivery via courier are stored in the fridge and accompanying items are appropriately marked with a fridge line sticker. Accompanying items must include a note to explain that fridge items will be delivered separately to the rest of their items to enable the cold chain to be maintained.

Ensure that the pharmacist on duty is available to supervise the handing over of all items for delivery.

A delivery must be booked using the couriers specified Cold Chain Services (refer to booking procedure with courier in the “cold chain courier” folder),

Select a delivery maintaining 2– 8°C unless the item requires shipping at a different temperature.

The cold chain item must be kept in the fridge until the courier arrives to accept the delivery.

Confirm with the courier that the delivery will be maintained at the booked temperature range.

Confirm details of all prescriptions to be delivered.

The courier must scan a barcode sticker for each item. The pharmacy retains a copy of the barcode which is also the tracking number.”

6.56.9 “19.17 Unsuccessful cold chain delivery via courier

In the event of an unsuccessful delivery, the courier will leave a ‘Missed Delivery’ card, stating the date and time of the attempted delivery along

with details of how to contact the courier to arrange the redelivery. The patient can then rearrange delivery for a convenient time by telephone or Internet.

We operate to a 48 hour maximum window for cold chain deliveries and the courier will keep the cold chain intact until successful delivery for up to 48 hours. After 48 hours the items will be returned to the pharmacy and the pharmacy will contact the patient to rearrange delivery.”

6.56.10 “19.18 Breach of Integrity of Cold Chain

The courier ensures temperature integrity throughout the supply chain, from point of collection & goods-in to pharmaceutical storage to final delivery.

The cold chain service is a dedicated, fully monitored and temperature controlled delivery service. However, in the event of any breach in the integrity of this service, the system automatically alerts the delivery driver that the cold chain has not been kept intact.

Where such an event occurs, the courier is instructed to leave a ‘Missed Delivery’ card and also inform the pharmacy that the delivery was unsuccessful due to a breach of the cold chain. The pharmacy must arrange for immediate re-delivery of the items via courier and the return of the items that have failed to be delivered to the pharmacy by the courier. Items subject to a cold chain breach may not be re-used and must be segregated from the pharmacy stock.”

6.57 SOP 23 ‘Controlled Drugs: Delivery’ states:

6.57.1 “23.5 Delivery of Schedule 2 & 3 CDs

A robust audit trail is essential when controlled drugs are involved. The delivery can be made to a person who is not the patient (the patient must have given authorisation for a representative to take receipt of CDs on their behalf). A Controlled Drugs Delivery Sheet must also be filled in for CD deliveries in addition to the Delivery Log sheet.

CDs must be in a separate bag to any other medication being delivered and the bags should be attached together.

CDs and any other medicines on that patient’s delivery must be stored in the lockable compartment of the delivery van and out of sight.

The delivery van must be kept locked at all times when the driver is not in the vehicle.

The delivery driver/courier must sign the back of the prescription as the representative when accepting the CD for delivery.

The delivery driver/courier must check the identity of the person accepting the delivery to ensure that it is the patient or authorised representative (passport, driving licence or government approved photo

ID card are acceptable forms of ID). A delivery cannot be left with anyone who is not the patient or their authorised representative.

All entries in the CD register must be made when the medication leaves the pharmacy premises. The delivery driver/courier must be entered as the 'person collecting'.

The prescription must be retained in the pharmacy until the delivery driver returns the appropriate paperwork signed by the patient or representative to confirm successful delivery or the patient signature is confirmed online if delivered by courier."

6.58 "23.7 Successful Schedule 2 & 3 Delivery

6.58.1 *The delivery driver/courier must check the identity of the person accepting the delivery to ensure that it is the patient or authorised representative. A delivery cannot be left with anyone who is not the patient or their authorised representative.*

For all successful deliveries the Controlled Drug delivery sheet signed by the patient or online courier delivery record should be cross-referenced with the prescription and CD register prior to the prescription being processed as part of the end of day procedure."

6.59 "23.8 Unsuccessful Schedule 2 & 3 Delivery via pharmacy driver

6.59.1 *Unsuccessful deliveries sent with a pharmacy driver must be returned to the pharmacy on the same day and entered back into the CD register where appropriate with an explanation. These must then be secured in the CD cabinet where appropriate."*

6.60 "23.9 Unsuccessful Schedule 2 & 3 Delivery via courier

6.60.1 *Unsuccessful deliveries sent with a courier must be returned to the pharmacy on the same day and entered back into the CD register where appropriate with an explanation. These must then be secured in the CD cabinet where appropriate. Where the time of attempted delivery means that the return cannot be made on the same day, the courier will store the drugs at their approved warehouse overnight.*

When a failed delivery occurs, the tracking service will notify the pharmacy and the patient of the failed delivery so that delivery can be re-arranged for the patient at the next convenient time or returned to the pharmacy."

6.61 "23.10 Note re Use of Couriers for Controlled Drugs Deliveries

6.61.1 *The courier has pharma grade specialist facilities to meet specific quality and validation requirements for healthcare products. This includes Home Office licensed controlled drug stores."*

6.62 Based on the information before it, the Committee was satisfied that the Applicant had provided information sufficient to show that there would be compliance with paragraph 8(1) of Schedule 4.

- 6.63 The Committee considered whether the Applicant had explained the arrangements which ensure that, for appliances which require fitting/measuring, a registered pharmacist measures/fits them.
- 6.64 The Committee noted that in the application form, in response to the question as to whether they were undertaking to provide appliances, the Applicant had stated “NA”. The Committee noted however that the SOPs as provided with the appeal sets out how the Applicant was proposing to deal with any prescriptions which were presented to it for items that require measuring or fitting.
- 6.65 The Committee noted the Applicant’s SOPs state:
- 6.66 SOP 9 ‘*Pharmaceutical & Legal Assessment*’:
- 6.66.1 “9.9 Items Requiring Measuring and Fitting
- Where a prescription is received for an item that requires measuring or fitting the patient should be contacted and informed that these items are not available from this pharmacy as we do not provide a measuring and fitting service. Patients should be signposted to at least two other providers of the service in their area. (see signposting SOP)”*
- 6.67 SOP 26 ‘*Support for Self-Care, Signposting and Health Promotion*’:
- 6.67.1 “26.14 Items Requiring Measuring and Fitting
- Where a prescription is received for an appliance or stoma appliance customisation or any item that requires measuring or fitting the patient must be contacted and informed that these items are not available from this pharmacy as we do not provide a measuring and fitting service. Patients must be signposted to at least two other providers of the service in their area. (see signposting SOP)”*
- 6.68 The Committee was of the view, that whilst the Applicant would not be able to provide any appliances, it had been provided with information sufficient to show that there would be compliance with paragraph 8(4) of Schedule 4.
- 6.69 The Committee considered whether the Applicant had explained what containers will be “suitable” for posted/delivered items.
- 6.70 The Committee noted that SOP 18 ‘*Bagging-Up*’ states:
- 6.70.1 “18.7 Choice of Packaging
- Choice of packaging will depend on the nature of the items being delivered and the appropriate level of protection must be used to ensure that the item can withstand the normal rigours of the delivery process.*
- All packaging must have the tamper proof seals provided in the pharmacy attached to the packaging so that any tampering with the packaging will be evident.*

Medicine for local delivery which is not fragile and to be delivered by the delivery driver can be packaged in the [sic] using the pharmacy bags supplied for standard prescription items.

DO NOT use normal cardboard boxes. When cardboard boxes are required ALWAYS use the re-enforced boxes that are purchased for delivery purposes.

For postal items, either:

At the very least - padded envelopes even for non-fragile items as this will help to ensure the integrity of the manufacturers packaging.

*For most items - bubble wrap and where necessary, polystyrene filler, placed within a cardboard box. **use the re-enforced cardboard boxes***

Large or any fragile medicines should be packed into the re-enforced cardboard boxes with bubble packaging and filling material to protect from damage.

*Coldchain items should be bubble wrapped and placed in Styrofoam filled re-enforced cardboard boxes and kept in the DELIVERIES FRIDGE (rather than the storage fridge) with the “FRAGILE” and “FRIDGE LINE” stickers attached. The courier company will transport the boxes in vans with cold chain sections that protect the integrity of the box (“cold ship” packaging) and are fully monitored – typically at 2 to 8 degrees Celsius range - (see delivery SOP). Pharmacy staff should be aware that some thermolabile products can be damaged by excessive cold as well as heat. Items such as ice packs can cause freezing in medicines which is damaging to them and such items **must not be used.**” [Applicant’s emphasis]*

- 6.71 Based on the information before it, the Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 8(15) of Schedule 4.

Refusal to provide drugs or appliances ordered

- 6.72 The Committee asked itself how the Applicant will be satisfied that when dispensing a repeatable prescription other than on the first occasion, that the patient is still using the medication, is not suffering from any side effects, the medicine regime has not changed in any way and there has been no changes to the patient’s health, which may indicate the desirability of review the patients treatment.

- 6.73 The Committee noted SOP 34 ‘Repeat Dispensing’ states:

6.73.1 “34.10 Prescription reception

...

The pharmacy record card must be completed and attached to a RA and an entry made on each occasion a dispensing takes place.

Any amendments to the RD, e.g. items not issued or change to expected interval must be recorded in the comment section of the pharmacy copy of the card."

6.74 "34.11 Pharmaceutical & Legal Assessment

6.74.1 *Terms of Service states that a pharmacy must, when providing drugs in accordance with a repeatable prescription the importance of only requesting those items which they need. Patients should be so advised either by phone or through the inclusion of written information with delivered medication.*

The pharmacist should telephone and speak with the patient before issuing a repeat and ensure:

They are taking or using, and likely to continue to take or use the medicine or appliances appropriately

Advise the patient that they should only order items that they need

Check that the patient is not suffering any side effects which may suggest they need a review of their medication

Check that the patient's regimen has not been changed since the prescriber authorised the repeatable medication.

Check that there has not been any change to the patient's health since prescription was authorised

Provide advice and encourage patients with long term, stable medical conditions to discuss repeat dispensing of their medicine with their prescriber.

Any interventions, referrals (to the patient's GP or otherwise) or refusal to supply decisions which are deemed to be clinically significant should be recorded on the Intervention and Referral Form which must be shared with the patient's GP.

The prescriber must have signed the RA. The RDs will not be signed but will be numbered as appropriate. The RA will detail the specific number of issues and, if appropriate, the dispensing interval."

6.75 The Committee was therefore satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 9(4) of Schedule 4.

Further activities to be carried out in connection with the provision of dispensing services

6.76 The Committee considered whether the Applicant had explained how appropriate advice about the benefits of repeat dispensing is given to any patient who (i) has long term, stable medical condition (that is, a medical

condition that is unlikely to change in the short to medium term), and (ii) requires regular medicine in respect of that medical condition.

6.77 The Committee noted SOP 34 '*Repeat Dispensing*' states:

6.77.1 "34.10 Prescription Reception

Appropriate advice about the benefits of repeat dispensing must be given to any patient who:

has a long term, stable medical condition (that is, a medical condition that is unlikely to change in the short to medium term); and,

requires regular medicine in respect of that medical condition, including, where appropriate, advice that encourages the patient to discuss repeat dispensing of that medicine with a prescriber at the provider of primary medical services whose patient list the patient is on.

Such advice will be provided by the Pharmacy using its permissible methods of non face-to-face contact with patients.

On receipt of a repeatable prescription from the patient, either in the post or collected from the surgery for the first time, the pharmacy staff should ensure that the patient fully understands the Repeat Dispensing Process and is provided with a patient information leaflet that outlines the benefits of the service.

Check to confirm if the patient has a long term, stable medical condition that requires regular medicine in the short to medium term and ensure relevant patients have the scheme explained to them."

6.78 "34.11 Pharmaceutical & Legal Assessment

6.78.1 *The pharmacist should telephone and speak with the patient before issuing a repeat and ensure:*

...Provide advice and encourage patients with long term, stable medical conditions to discuss repeat dispensing of their medicine with their prescriber."

6.79 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 10(1) of Schedule 4.

Disposal service in respect of unwanted drugs

6.80 The Committee considered whether the Applicant had explained how it will safely and effectively accept and dispose of unwanted drugs presented to it for disposal.

6.81 The Committee noted SOP 24 '*Controlled Drugs: Collection and Disposal of Patient Returns*' states:

6.81.1 “24.5 Patient Returned Medication

This service is available to all patients living in England.

Patients or their representatives may not return and medicines directly to the pharmacy and must follow the procedures set out in this SOP. [Applicant’s emphasis]

Patients should be referred to the ‘Returning unwanted medication’ page on the website for information.

To arrange the return of unwanted medicines to the Pharmacy the patient must telephone and speak to a member of the dispensary team. For controlled drugs this must always be the pharmacist on duty.

The process for returning medication must be explained to the patient.

Each return will be made by booking an appointment for the pharmacy’s driver to visit the patient’s home to collect the returned medication or by sending the appropriate packaging to the patient to arrange for return by Royal Mail – Note the Royal Mail website refers to a prohibition on carrying “controlled drugs” but this refers only to illicit controlled drugs and not those supplied under the direction of a physician.”

6.81.2 “24.7 Return by Royal Mail

The pharmacist must

Speak to the patient about the return and clarify the items being returned.

Assess the items for suitability for return by Royal Mail

If items are suitable for return by Royal Mail then make a note on the PMR and arrange to send the appropriate packaging to the patient for safe return (refer to bagging up SOP for appropriate packaging)

If items are not suitable for return by Royal Mail (eg clinical or contaminated waste) then provide the patient with details of their local procedures for disposal.

Send the packaging to the patient along with the instructions for appropriate packing of the goods

Contact the patient to ensure that the packaging has been received

Provide signposting via phone or email to other pharmacies where the patient prefers to dispose of unwanted medicines locally.”

6.81.3 “24.8 Handling Patient-Returned CDs from Delivery Driver

6.81.4 Drivers need to:

Be aware that they cannot accept patient returns from patients without prior arrangement. The driver must notify the patient to follow the “returning unwanted medication” process as set out on the website.

Ensure that appropriate packaging is within the van prior to starting the journey as the patient may not have requested the correct type or there may be a requirement for additional packaging.

Pharmacy staff need to:

If CDs have been identified, immediately on receipt from the driver, secure them in a bag, clearly marking on ‘Patient-returned CDs for destruction’ and include the date of return; place the bag in the CD cabinet away from pharmacy stock until they can be destroyed.

As soon as possible, Refer to the ‘Returned medicines form’ to make the entry in the ‘Patient returned CD register’, to record the CD that require destruction at a later date.”

6.82 SOP 25 ‘The Safe and Effective Receipt and Disposal of Medicines’ states:

6.82.1 “25.6 Process for Patients to Return Medication

Patient Returned Medication

Patients or their representatives MAY NOT return and [sic] medicines directly to the pharmacy and must follow the procedures set out in this SOP.

This service is available to all patients living in England.

Patients can be referred to the ‘Returning unwanted medication’ page on the website for information.

To arrange sending medication back to the Pharmacy the patient must telephone and speak to a member of the dispensary team.

Patients may

Arrange collection by the Pharmacy driver at an appointed time, or

Send unwanted medication back to the Pharmacy via courier (at the pharmacy’s cost), or Royal Mail (subject to risk assessment of contents by the RP in advance) or,

The Pharmacy can arrange for medication to be collected by our specialist waste management contractor.

Advise patient of their other options to dispose of unwanted or expired medication if none of these options is suitable for them (signposting to local pharmacies).

Explaining the Process to Patients

Check which patient or patients the medication belonged to.

Check the relevant PMR to identify any hazardous / dangerous drugs or items that have been dispensed and could potentially form part of the return.

Ask the patient to identify the type of medication being returned.

If there is any item considered dangerous, such as a cytotoxic, inform the patient that we will collect items using the specialist waste management contractor and arrange for that collection to take place at a convenient time.

Go through the “unwanted medicines card” (available from the CPE website) over the phone with the patient”

6.82.2 “25.7 Process for accepting patient returns by the Driver

Confirm that a collection of unwanted medication for disposal has been booked. Returns without a booking should only happen in exceptional circumstances as this increases the chance that the proper process for segregation of medicine has not been followed.

Ensure you are fully equipped with the utensils in your vehicle to accept unwanted medication as patients may have placed unwanted medication into incorrect bags.

Wear appropriate protective clothing where there is a requirement to handle any returned waste.

Identify any controlled drugs (check with the pharmacist if necessary); segregate these and place in a labelled clear bag for the pharmacist for denaturing and disposal. For further guidance read SOP Controlled Drugs: Disposal of Patient returned medication’.

Identify any sharps and ask the customer to take these back if it safe to do so, signposting to the most appropriate route of disposal.

Identify any cytotoxic or other hazardous waste (check with the pharmacist where necessary).

Identify any flammable waste and store separately until this can be removed by the waste contractor.

Where large quantities of the same medicine are being returned, then report this to the pharmacist as this could indicate a compliance issue requiring intervention.

Complete the ‘Patients Returns Sheet’ detailing the patients name and address, also if relevant their representatives name.

Store returned medicines in the quarantine area of the van for transport.

The returnable items can be taken back to the pharmacy for destruction.

Ensure medicines are not visible in the vehicle at all times.”

6.82.3 “25.9 Return by Royal Mail

The pharmacist must

Speak to the patient about the return and clarify the items being returned.

Assess the items for suitability for return by Royal Mail

If items are suitable for return by Royal Mail then make a note on the PMR and arrange to send the appropriate packaging to the patient for safe return (refer to bagging up SOP for appropriate packaging)

If items are not suitable for return by Royal Mail (eg clinical or contaminated waste) then provide the patient with details of their local procedures for disposal.

Send the packaging to the patient along with the instructions for appropriate packing of the goods

Contact the patient to ensure that the packaging has been received

Provide signposting via phone or email to other pharmacies where the patient prefers to dispose of unwanted medicines locally.”

6.82.4 “25.10 Disposal of returned medicines

Use the specialist waste management company to provide safe and secure disposal of unwanted medicines by collection of unwanted medicines from patients and residential homes.

Unwanted medicines collected by the driver must be sorted and placed in disposal units / containers provided by the NHSCB or a waste contractor retained by the NHSCB ready for waste management services to collect.”

- 6.83 Based on all of the information before it, the Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraphs 13 - 15 of Schedule 4.

Promotion of healthy lifestyles

- 6.84 The Committee considered whether the Applicant had explained how it will safely and effectively promote healthy lifestyles.
- 6.85 The Committee noted SOP 27 ‘Promotion of Healthy Living, Lifestyle & Health Campaigns’ states:

6.85.1 “27.3 Identification of patients for promotion of Healthy Lifestyles

Identification can take three forms, namely, passive, active, or as part of the repeat (or normal) dispensing process.

Active patients will be those who have chosen to access the Lifestyle Questionnaires via the website or returned them by post and who are then identified from the results as patients to whom further information should be sent, or who should be called to follow up on the results and offer additional support and information. All patients who have prescriptions dispensed or purchase medicines from the pharmacy will be asked to fill in the Lifestyle Questionnaire which will ask for details such as existing medical conditions, height, weight and also lifestyle questions such as whether a patient is a smoker and how much exercise they normally have on a weekly basis.

Passive patients are those where the identification happens as part of another interaction with the patient, but where the patient does not appear to be actively seeking additional assistance. For example, the dispensing of a prescription which identifies the patient as having high blood pressure / diabetes etc.

As part of repeat dispensing process (or during any other interaction with a patient) staff should record the information provided by patients on the PMR system. Where a patient provides information that indicates that they would benefit from promotion of healthy lifestyles they should

be recorded as a ‘target patient’ and the appropriate information that is relevant to them should be provided.

Leaflets will be delivered to patients with their medication. Those identified as having medical conditions such as diabetes, coronary heart disease, COPD, Asthma, high blood pressure, smokers, overweight individuals, etc. or being at risk from them or other conditions will also receive targeted campaigns. The website, app and email newsletters will also be used to promote healthy lifestyles via the health promotion zone.”

6.85.2 “27.4 Health Campaigns & Community Engagement Exercise

Terms of Service require participation in a maximum of 2 campaigns per financial year, but you should agree to take part in all campaigns where practicable.

The Pharmacy will take part in national health campaigns to promote public health messages to patients across England. This will be achieved by sending out leaflets with prescriptions during specific targeted campaign periods and providing additional advice and learning resources via the website on the health promotion zone.

...We will also offer help and support on our website and direct patients to appropriate links for the health campaigns. This will ensure that

patients across the UK are able to easily access information about health campaigns at all times.”

- 6.86 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 16 – 18 of Schedule 4.

Prescription linked intervention

- 6.87 The Committee considered whether the Applicant had explained how it will assess whether persons require prescription linked intervention advice because they have diabetes, are at risk of coronary heart disease, smoke or are overweight.

- 6.88 The Committee noted SOP 27 ‘*Promotion of Healthy Living, Lifestyle & Health Campaigns*’ states:

6.88.1 “27.6 Long Term Conditions

If it is appropriate to provide advice the pharmacist should provide any advice necessary and within their area of competency. Where advice is provided it should be recorded on an Intervention & Referral form. Any advice given should always aim to include counselling on healthy lifestyle as well as management of the long-term condition.

If it is not appropriate to provide advice the patient should be referred to the appropriate health or social care provider or support organisation (see Signposting SOP). Where advice cannot be provided it should be recorded on an Intervention & Referral form along with the referral organisation.

For specific groups of patients (those with diabetes, at risk of coronary heart disease, especially those with high blood pressure, and patients who smoke or who are overweight) the pharmacists must provide advice without face-to face interaction (eg telephone, Live video, via the website). Such advice should be backed up, as appropriate, by the provision of written material such as leaflets.”

6.88.2 “27.7 Identification of patients for Support with Long Term Conditions

Identification can take three forms, namely, passive, active, or as part of the repeat (or normal) dispensing process.

Active patients will be those who have chosen to access the Lifestyle Questionnaires via the website or returned them by post and who are then identified from the results as patients to whom further information should be sent, or who should be called to follow up on the results and offer additional support and information. All patients who have prescriptions dispensed or purchase medicines from the pharmacy will be asked to fill in the Lifestyle Questionnaire which will ask for details such as existing medical conditions, height, weight and also lifestyle questions such as whether a patient is a smoker and how much exercise they normally have on a weekly basis.

Passive patients are those where the identification happens as part of another interaction with the patient, but where the patient does not appear to be actively seeking additional assistance. For example, the dispensing of a prescription which identifies the patient as having high blood pressure / diabetes etc.

As part of repeat dispensing process (or during any other interaction with a patient) staff should record the information provided by patients on the PMR system. Where a patient provides information that indicates that they would benefit from promotion of healthy lifestyles they should be recorded as a 'target patient' and the appropriate information that is relevant to them should be provided.

Leaflets will be delivered to patients with their medication. Those identified as having medical conditions such as diabetes, coronary heart disease, COPD, Asthma, high blood pressure, smokers, overweight individuals, etc. or being at risk from them or other conditions will also receive targeted campaigns. The website, app and email newsletters will also be used to promote healthy lifestyles."

- 6.89 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 17 of Schedule 4.

Health campaigns

- 6.90 The Committee considered whether the Applicant had explained how it will safely and effectively participate in public health campaigns, if and to the extent required by the Commissioner.
- 6.91 The Committee noted SOP 27 '*Promotion of Healthy Living, Lifestyle & Health Campaigns*' states:

6.91.1 "27.4 Health Campaigns & Community Engagement Exercise

The Pharmacy will take part in national health campaigns to promote public health messages to patients across England. This will be achieved by sending out leaflets with prescriptions during specific targeted campaign periods and providing additional advice and learning resources via the website on the health promotion zone.

The pharmacy will also take part in at least one approved community engagement exercise in relation to the promotion of health living each financial year.

Patients will be directed to the learning resources via email, text and other non face-to-face communication so that they are aware of the campaign.

Patients should also be assessed for participation in at least one clinical audit and whichever of the following that the NHSCB specifies—

(i) a clinical audit carried out in a manner which is compatible with the NHSCB's arrangements for the receiving and processing of data from the audit, or

(ii) a policy based audit (to support the development of the commissioning policies of the NHSCB) carried out in a manner which is compatible with the NHSCB's arrangements for the receiving and processing of data from the audit.

We will also offer help and support on our website and direct patients to appropriate links for the health campaigns. This will ensure that patients across the UK are able to easily access information about health campaigns at all times.

The Pharmacy will use the opportunity when dispensing prescriptions for patients who have conditions such as diabetes, heart disease, obesity and high blood pressure, to offer health advice over the phone or provide them with leaflets about their conditions. Patients will also be able to speak to the pharmacist regarding information about the campaigns. Advice and help will be available to patients during opening hours of the pharmacy and patients can access information on our pharmacy website at all times. This ensures the uninterrupted provision of the service to patients across England."

- 6.92 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 18 of Schedule 4.

Signposting

- 6.93 The Committee considered whether the Applicant had explained how it will provide information to users of the pharmacy about other health and social care providers and support organisations.

- 6.94 The Committee noted SOP 26 'Support for Self-Care, Signposting and Health Promotion' states:

6.94.1 "26.10 Other Provider Organisations and Support Details

Details of local health and social care providers to whom patients can be referred as well as contact details for local patient and support groups can should [sic] be provided to patients via written mailshots, flyers sent with prescription deliveries, our website and by telephone or email."

6.94.2 "26.12 Signposting

Service Description

To minimise inappropriate use of health and social care services and support services, patients who require further support, advice or treatment which cannot be provided by the pharmacy, on other health and social care providers or support organisations who may be able to

assist the person must be given sufficient information to enable them to access those services. Where appropriate, this may take the form of a referral.”

6.94.3 “26.13 Patient Identification

Identification can take place during any interaction that the patient has with the pharmacy staff. In particular, staff should consider the results from the identification of patients for the promotion of healthy lifestyles and those who have filled in the Lifestyle Questionnaire on the website.

Staff should always consider that in order to minimise inappropriate use of health and social care services and of support services and person who:

requires advice, treatment or support that we cannot provide; but

we are aware of another provider of health services who is likely to be able to provide that advice, treatment or support.

We must provide the patient with contact details of that provider and, where appropriate, refer the person to the provider. At least two providers should be identified if this is possible.”

- 6.95 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraphs 19 – 20 of Schedule 4.

Support for self-care

- 6.96 The Committee considered whether the Applicant had explained how it will provide advice and support to people caring for their families.

- 6.97 The Committee noted SOP 26 ‘Support for Self-Care, Signposting and Health Promotion’ states:

6.97.1 “26.8 Patient Identification

As part of repeat dispensing process / medicine sale or during any other interaction with a patient staff should record the information provided by patients on the PMR system. Where a patient provides information that indicates that they would benefit from support for self-care they should be recorded as a ‘target patient’ and the appropriate information that is relevant to them should be provided and should include:

treatment options, including advice on the selection and use of appropriate drugs which are not prescription only medicines; and

on changes to the patient’s lifestyle.”

6.97.2 “26.9 Service outline

Upon receipt of a request for help with the Support for Self-Care, including treatment of minor illness and long-term conditions, pharmacy staff should consider available resources and provide general information and advice on how to manage illness.

If appropriate, access the patient's Summary Care Record / National Care Records Service to see if it assists in delivery of the service.

...The pharmacist should provide advice on the appropriate use of non-prescription medicines which can be used in the self-care of the relevant minor illness and / or long-term conditions."

- 6.98 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraphs 21 – 22 of Schedule 4.

Discharge medicines service

- 6.99 The Committee considered whether the Applicant had explained how it will provide advice, assistance and support to and in respect of a health service patient – (a) recently discharged from hospital who is referred to P for advice, assistance and support in respect of the patient's medication regimen by the staff of the hospital in which the patient stayed; or (b) who is otherwise referred to P for advice, assistance and support in respect of the patient's medication regimen by the staff of an NHS trust and NHS foundation trust as part of arrangements linked to the transfer of care between different providers of NHS services.
- 6.100 Further, the Committee considered whether the Applicant had explained what procedures it has in place for checking referrals for the discharge medicines service.
- 6.101 The Committee noted SOP 28 'Discharge Medicines Service ("DMS")' states:

6.101.1 "28.3 Process

Every day the RP must check the pharmacy's NHS.net Connect system, PharmOutcomes and Refer to Pharmacy for referrals to the DMS. Pharmacy contractors must consider any communication in the following form and manner as constituting a referral: "Any written patient information received by a community pharmacy via secure electronic message from an NHS trust or other provider of NHS services concerning a patient's discharge to usual primary care services and their medicines regimen".

6.101.2 "28.4 Consent

Obtain and record the informed consent from the patient prior to provision of the service using the consent form. As part of obtaining consent discuss the requirements for data sharing. Inform the patient that any information discussed as part of the service may be shared with their GP."

6.101.3 “28.5 DMS Stages

It is expected that all patients referred to the pharmacy will receive all three stages of the service. Note that stages 1, 2 and 3 of the service may occur in parallel and first contact with the patient (as defined in the NHS Discharge Medicines Service toolkit) could happen at any stage in the process.”

6.101.4 “28.6 DMS Stage 1 (within 72 hours of referral excluding times when the pharmacy is not open)

The community pharmacy receives a discharge referral. A clinical review is undertaken by a community pharmacist following receipt of a patient referral. The community pharmacy team may contact the referring NHS trust contact or the PCN pharmacy team to discuss any concerns (eg an important medicine the patient usually takes is omitted on the discharge referral) and to seek clarification about the discharge referral.”

6.101.5 “28.7 Considering the appropriateness of any medication changes prior to discharge

DMS requests will not necessarily all be in the same form.

Summary Care Record / National Care Records Service Access - If appropriate, access the patient’s Summary Care Record / National Care Records Service to see if it assists in providing the service

The pharmacist must review the actions requested in the DMS and consider whether the actions requested are, in the pharmacists clinical judgement, appropriate.

For actions that are considered appropriate the pharmacist must;

Use the information in the referral, to compare (as far as possible) the patient’s medicines at discharge to those they were taking before admission to hospital.

Check any prescriptions issued to be dispensed to assess whether any changes are appropriate and identify any areas of concern.

Where necessary, discuss changes that may be appropriate or raise any issues of concern identified, to the extent that in accordance with the pharmacist’s clinical judgement, it appropriate to do so with—

(i) the staff of the hospital or other provider of NHS services that made the referral, and

(ii) any provider of primary medical services on whose patient list the patient is; and

keep and maintain records of the DMS referrals received and of any actions taken, as appropriate (in particular, to support delivery of stages 2 and 3 of the service).

REQUIRED ACTIONS AS PER NHS GUIDANCE”

6.101.6 “28.8 DMS Stage 2

The community pharmacy receives the first prescription following discharge. The pharmacist or pharmacy technician will ensure medicines prescribed post-discharge take account of the appropriate changes made during the hospital admission. If there are discrepancies, the pharmacy team will try to resolve them with the general practice, utilising existing communication channels. Alternatively, the community pharmacist may refer the patient to the PCN pharmacy team for a Structured Medication Review or other intervention.

If the pharmacy receives either a written or electronic prescription (or repeatable prescription) or EPS token and the pharmacy has received a request for Stage 2 of the DMS service either from Stage 1 or

Even without a referral to Stage 2, the pharmacy receives such a prescription as described above and the pharmacy is aware as a result of an earlier referral to Stage 2 or Stage 3 this is the first prescription for a medicinal product following the patient’s discharge from hospital, or a transfer of the patient’s care from another NHS service provider, AND

The pharmacy is aware that either the patient, or their carer wishes the pharmacy to provide Stage 2 of the DMS service then the pharmacy must provide the following service as part of Stage 2

Then the pharmacist must:

Review / perform a further review of any prescription

Summary Care Record / National Care Records Service Access - If appropriate, access the patient’s Summary Care Record / National Care Records Service to see if it assists in providing the service.

Specifically consider if in your clinical judgement appropriate account has been taken to any changes in the medication regimen during the patient’s stay in hospital or prior to the transfer of the DMS from another pharmacy.

Where you see areas of concern, raise those issues as appropriate with the patient’s GP

Keep and maintain records of the DMS referrals received and of any actions taken, as appropriate (in particular, to support delivery of stage 3 of the service).”

6.101.7 “28.9 DMS Stage 3

The NHS Discharge Medicines Service should also be used as an opportunity to engage with patients about their medicines on a shared decision-making basis. Whether the patient or their carer makes contact themselves for advice, a referral is received from an NHS trust on discharge or a prescription is received following prescribing changes, the pharmacist or pharmacy technician should take the opportunity to establish the patient’s understanding of their condition(s), their associated medications and how each medicine can be best administered to get optimum benefit and reduce unwanted side effects.

6.101.8 *The community pharmacy checks the patient’s understanding of their medicines regimen. The pharmacist or pharmacy technician will hold a discussion, adopting a shared decision-making approach, with the patient (or the carer if appropriate) to check their understanding of their post-discharge medicines’ regimen. The pharmacist or pharmacy technician will identify any adherence, clinical issues, outstanding questions or needs the patient may have regarding their medicines.”*

6.102 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraphs 22B and 22C of Schedule 4.

Websites and health promotion zones

6.103 The Committee considered whether the Applicant had explained how it will ensure that it has a website for use by the public for the purpose of accessing pharmaceutical services from those premises, on which there is an interactive page, clearly promoted to any user of the website when they first access it, which provides public access to a reasonable range of up to date materials that promote healthy lifestyles by addressing a reasonable range of health issues.

6.104 The Committee noted that SOP 26 ‘Support for Self-Care, Signposting and Health Promotion’ states:

6.104.1 “26.11 Health promotion zone on our website

The website allows patients to access pharmaceutical services via our interactive page.

Explaining the Interactive Page to Patients

The interactive page is promoted on the website so that when a patient first visits the website they are signposted to a range of up to date materials that promote healthy lifestyles.

The Superintendent Pharmacist is responsible for ensuring that a reasonable range of materials are accessible via the interactive page and that they address a reasonable range of health issues.

The health promotion zone may also includes [sic] details of current health campaigns and other information to promote healthy lifestyle

choices as well as providing access to the Lifestyle Questionnaire that is used to target health information to patients.”

- 6.105 The Committee was satisfied that it had been provided with information sufficient to show that there would be compliance with paragraph 28C of Schedule 4.

Summary

- 6.106 On the information before it, the Committee could be satisfied that there are procedures likely to secure the safe and effective provision of pharmaceutical services as required by Regulation 25(2)(b).
- 6.107 Pursuant to paragraph 9(1)(a) of Schedule 3 to the Regulations, the Committee may:
- 6.107.1 confirm the Commissioner’s decision;
 - 6.107.2 quash the Commissioner’s decision and redetermine the application;
 - 6.107.3 quash the Commissioner’s decision and, if it considers that there should be a further notification to the parties to make representations, remit the matter to the Commissioner.
- 6.108 In those circumstances given that the Committee has reached a different conclusion to the Commissioner, it determined that the decision of the Commissioner must be quashed.
- 6.109 The Committee considered whether there should be a further notification to the parties detailed at paragraph 19 of Schedule 2 of the Regulations to allow them to make representations if they so wished (in which case it would be appropriate to quash the original decision and remit the matter to the Commissioner) or whether it was preferable for the Committee to reconsider the application.
- 6.110 The Committee noted that representations on Regulation 25 had already been made by parties to the Commissioner, and these had been circulated and seen by all parties as part of the processing of the application by the Commissioner. The Committee further noted that when the appeal was circulated representations had been sought from parties on Regulation 25.
- 6.111 The Committee concluded that further notification under paragraph 19 of Schedule 2 would not be helpful in this case.

7 Decision

- 7.1 The Committee concluded that it was not required to refuse the application under the provisions of Regulation 31.
- 7.2 The Committee:
- 7.2.1 quashes the decision of the Commissioner; and

7.2.2 redetermines the application as follows -

7.2.2.1 the Committee was satisfied that the premises of the Applicant are not on the same site or in the same building as the premises of a provider of primary medical services with a patient list;

7.2.2.2 the Committee was satisfied that all essential services were likely to be secured without interruption during the opening hours;

7.2.2.3 the Committee was satisfied that all essential services were likely to be secured for persons anywhere in England;

7.2.2.4 the Committee was satisfied that pharmaceutical services were likely to be secured in a safe and effective manner; and

7.2.2.5 the Committee was satisfied that pharmaceutical services were likely to be secured without face to face contact.

7.2.2.6 The application is granted.

Case Manager
Primary Care Appeals